Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy

Leukemia

Volumn 25, Issue 10, 2011, Pages 1627-1631

  Cavallo, F ^a   Bringhen, S ^a   Milone, G ^b   Ben Yehuda, D ^c   Nagler, A ^d   Calabrese, E ^e   Cascavilla, N ^f   Montefusco, V ^g   Lupo, B ^a   Liberati, A M ^h   Crippa, C ⁱ   Rossini, F ^j   Passera, R ^k   Patriarca, F ^l   Cafro, A M ^m   Omede P ^a   Carella, A M ⁿ   Peccatori, J ^o   Catalano, L ^p   Caravita, T ^q   Musto, P ^r   Petrucci, M T ^e   Boccadoro, M ^a   Palumbo, A ^a   more..

^a UNIVERSITY OF TURIN   (Italy)

^b Ferrarotto Hospital   (Italy)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d SHEBA MEDICAL CENTER   (Israel)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h UNIVERSITY OF PERUGIA   (Italy)

ⁱ SPEDALI CIVILI   (Italy)

^j SAN GERARDO HOSPITAL   (Italy)

^k Radiochemistry Unit C/o SC Medicina Nucleare 2   (Italy)

^l SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^m OSPEDALE NIGUARDA CA GRANDA   (Italy)

ⁿ UNIVERSITY OF GENOA   (Italy)

^o SAN RAFFAELE HOSPITAL   (Italy)

^p UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^q S EUGENIO HOSPITAL   (Italy)

^r REFERRAL CANCER CENTER OF BASILICATA   (Italy)

more..

Author keywords

lenalidomide; mobilization; myeloma; novel agent; transplantation

Indexed keywords

BETA 2 MICROGLOBULIN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; LENALIDOMIDE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; STEM CELL MOBILIZATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; MALE; MIDDLE AGED; THALIDOMIDE; TRANSPLANTATION CONDITIONING;

EID: 80054018501     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.131     Document Type: Article

References (38)

1. Pasquini M. Part IFCIBMTR Summary Slides, 2005. CIBMTR Newsletter 2006; 12: 5-8. http://www.cibmtr.org/ReferenceCenter/Newsletters/PDF/Newsletter- May2006.pdf. (accessed July 30 2010).
2. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 1996; 335: 91-97. (Pubitemid 26240110)
3. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883. (Pubitemid 36532313)
4. Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M et al. High-dose therapy and autologous blood stemcell transplantation compared with conventional treatment in myeloma patients aged 55-65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005; 23: 9227-9233.
5. Goldschmidt H, Hegenbart U, Haas R, Hunstein W. Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 691-697. (Pubitemid 26156299)
6. Cottler-Fox MH, Lapidot T, Petit I, Kollet O, DiPersio JF, Link D et al. Stem cell mobilization. Hematology Am Soc Hematol Educ Program 2003, 419-437.
7. Bolwell B, Goormastic M, Andresen S. Durability of remission after ABMT for NHL: the importance of the 2-year evaluation point. Bone Marrow Transplant 1997; 19: 443-448. (Pubitemid 27102009)
8. Ketterer N, Salles G, Moullet I, Dumontet C, ElJaafari-Corbin A, Tremisi P et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998; 103: 235-242. (Pubitemid 28470825)
9. Russell NH, McQuaker G, Stainer C, Byrne JL, Haynes AP. Stem cell mobilisation in lymphoproliferative diseases. Bone Marrow Transplant 1998; 22: 935-940. (Pubitemid 28543054)
10. Boccadoro M, Palumbo A, Bringhen S, Merletti F, Ciccone G, Richiardi L et al. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica 2002; 87: 846-850. (Pubitemid 34851555)
11. Morris CL, Siegel E, Barlogie B, Cottler-Fox M, Lin P, Fassas A et al. Mobilization of CD34+ cells in elderly patients (4/70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 2003; 120: 413-423. (Pubitemid 36241497)
12. Perea G, Sureda A, Martino R, Altés A, Martínez C, Cabezudo E et al. Predictive factors for a successful mobilization of peripheral blood CD34+ cells in multiple myeloma. Ann Hematol 2001; 80: 592-597. (Pubitemid 33061999)
13. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319-4323. (Pubitemid 35266292)
14. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431-436. (Pubitemid 46630462)
15. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106: 4050-4053. (Pubitemid 41775908)
16. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16-19.
17. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005; 23: 630-639. (Pubitemid 46224241)
18. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617. (Pubitemid 36741588)
19. Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006; 91: 1498-1505. (Pubitemid 44736116)
20. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007; 21: 2035-2042. (Pubitemid 47299979)
21. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 2009; 15: 718-723.
22. Mazumder A, Kaufman J, Niesvizky R, Lonial S, Vesole D, Jagannath S. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia 2008; 22: 1280-1281. (Pubitemid 351833803)
23. Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D et al. Superiority of thalidomide and dexamethasone over vincristinedoxorubicin- dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 35-39. (Pubitemid 40967171)
24. Breitkreutz I, Lokhorst HM, Raab MS, Holt B, Cremer FW, Herrmann D et al. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia 2007; 21: 1294-1299. (Pubitemid 46831819)
25. Moreau P, Hulin C, Marit G, Caillot D, Facon T, Lenain P et al. Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial. Leukemia 2010; 24: 1233-1235.
26. Mark T, Stern J, Furst JR, Jayabalan D, Zafar F, LaRow A et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant 2008; 14: 795-798. (Pubitemid 351773154)
27. Paripati H, Stewart AK, Cabou S, Dueck A, Zepeda VJ, Pirooz N et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 2008; 22: 1282-1284. (Pubitemid 351833805)
28. Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129: 776-783. (Pubitemid 40904528)
29. Goldschmidt H, Lokhorst HM, Bertsch U, van der Holt B, el Jarari L, Salwender H-J et al. Successful harvesting of peripheral hematopoietic stem cells after induction treatment with bortezomib, adriamycin, dexamethasone (PAD) in patients with newly diagnosed multiple myeloma (MM). Blood 2008; 112: (abstract 3470).
30. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
31. http://ctep.cancer.gov: NCI Common terminology criteria for adverse events, (version 3.0).
32. Hilbe JM. Logistic Regression Models. Chapman & Hall/CRC Press, 2009.
33. Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 2009; 114: 1729-1735.
34. Cook RJ, Vogl D, Mangan PA, Cunningham K, Luger S, Porter DL et al. Lenalidomide and stem cell collection in patients with multiple myeloma. J Clin Oncol 2008; 26: (abstract 8547).
35. Tricot G, Cottler-Fox MH, Calandra G. Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplant 2010; 45: 63-68.
36. Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, Rowley SD et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867-1874. (Pubitemid 41208607)
37. Koh KR, Janz M, Mapara MY, Lemke B, Stirling D, Dörken B et al. Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis. Blood 2005; 105: 3833-3840. (Pubitemid 40656125)
38. Anderson G, Gries M, Kurihara N, Honjo T, Anderson J, Donnenberg V et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 2006; 107: 3098-3105.